Mastercard Platform Delivers Data-Driven Treasury Intelligence

On display at Sibos is the latest innovation in Mastercard’s expansive services suite which will be…

Slate Asset Management Provides Fleet Financing to Move About Group AB to Support Rollout of Electric Vehicles and Charging Infrastructure Across Europe

LONDON–(BUSINESS WIRE)–Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that…

LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™

Innovate UK, part of UK Research and Innovation (UKRI), has awarded LabGenius with a SMART grant…

Notice Regarding Yayoi Kusama’s “Pumpkin” Exhibit at Benesse Art Site Naoshima

NAOSHIMA, Japan–(BUSINESS WIRE)–#BenesseArtSite–Benesse Art Site Naoshima is pleased to announce that Yayoi Kusama’s “Pumpkin,” the outdoor…

Strategy Analytics/TechInsights: Industrial, Automotive and Utilities Remain the Biggest Verticals for IoT Connections During 2022-30

Industrial will be the leading vertical followed by Automotive with highest CAGR in 2030 BOSTON–(BUSINESS WIRE)–Strategy…

Fuji Speedway Hotel Debuts as the First Hotel in the Unbound Collection by Hyatt Brand in Japan

Set amid Mount Fuji, the one-of-a-kind luxury hotel provides the ultimate motorsports experience at the iconic…

Valbiotis Accelerates Its Marketing Strategy

Internationally, the signing of licensing or distribution partnerships with major players in nutrition and healthcare. In…

Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the pricing of an upsized underwritten public offering…

mesm Tokyo, Autograph Collection: English Playwright William Shakespeare’s Masterpiece “Romeo and Juliet” Themed Lunch & Dinner Programs Offered Limited Time Only

TOKYO–(BUSINESS WIRE)–mesm Tokyo, Autograph Collection will offer a lunch and dinner program featuring English playwright William…

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

– OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary…